CVS will cover Gilead hepatitis C treatment over new AbbVie drug

CVS Health Corp., one of the largest U.S. managers of drug benefits, said it would give the hepatitis C treatment from Gilead Sciences Inc. preferred status and cover a new competing treatment from AbbVie Inc. only as an exception, CNBC reported on Monday.

Shares in Gilead rose nearly 3 percent after the report that CVS would favor the treatment, which can cost about $84,000, or $1,000 per pill. Its cost has spurred a national debate about whether drug prices had soared too high.

Two weeks ago, the nation's largest drug benefits manager, north St. Louis County-based Express Scripts Holding Co., said it would cover a competing, newly approved treatment from AbbVie rather than Gilead, and Gilead shares fell sharply.


Labels: , , ,